市場調査レポート

商品コード

1447729

薬剤スクリーニング市場の評価：コンポーネント・サンプルタイプ・エンドユーザー・地域別の機会および予測 (2017～2031年)

Drug screening Market Assessment, By Components, By Sample Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 229 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 676,845円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 857,337円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,233,362円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.41円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の薬剤スクリーニングの市場規模は、2023年の70億2,000万米ドルから、2024年から2031年の予測期間中は14.65%のCAGRで推移し、2031年には209億6,000万米ドルの規模に成長すると予測されています。

世界の薬剤スクリーニング市場の成長は、アルコールと薬物の消費の増加、薬物検査製品の技術の進歩、規律および安全対策維持のための適切な薬剤スクリーニング関連の規則・規制の実施の増加など、さまざまな要因によって推進されています。R&D活動への投資の拡大、複数のトップ企業の存在、M&A、提携、販売契約、頻繁な新製品の発売などの共同事業も世界の薬剤スクリーニング市場の成長をさらに加速させています。

精神作用物質の消費の増加

薬物やアルコールの消費の増加は、薬剤スクリーニング市場を加速させています。不安、ストレス、うつ病、孤立、社会的援助へのアクセスの制限などが、人々による薬物乱用を増加させています。事故、自己破壊活動、さらには死亡といった多くの悪影響をもたらす薬物の剰摂取の事例が増加していることが薬剤スクリーニングサービスの必要性を高めています。World Drug Report 2023によると、2021年の薬物使用者の総数は2億9,600万人と推定されています。また、大麻が世界の人々にもっとも広く使用されている薬物であると推定されています。このような薬物乱用の増加は、保健医療システムの負担につながり、厳格な薬剤スクリーニング活動に従うことの重要性を強調しています。さらに、薬剤スクリーニングは、交通事故のような事故の増加ケースを最小限に抑えるために不可欠な役割を果たしており、これも市場成長を促進する主要な要因として作用しています。

政府の取り組み

政府は、国内の薬物乱用事例を監視するための政策やプログラムを継続的に開発することで、薬物乱用を管理・抑制する上での重要な役割を果たしています。政府は、非常に効率的な薬物乱用検出製品やデバイスを開発するためのR&D活動の促進に関与しています。例えば、National Institute on Drug Abuseは、薬物乱用の理解と抑制に関する科学的研究の支援に取り組む連邦機関であり、世界の薬物乱用を制御するためのR&D活動の推進に重点を置いています。

迅速検査デバイスに対する需要の増加

コンポーネント別では、迅速検査デバイスが人気を集めており、同部門がより速いペースで成長すると予想されています。これらのデバイスは投与が簡単で、費用対効果が高く、結果が早く出るため、市場で非常に多く過使用されています。この需要が高まりから、複数の大手企業が製品ポートフォリオにこの製品を追加しています。

当レポートでは、世界の薬剤スクリーニングの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
コンポーネント別
- 迅速検査デバイス
- 機器
- 消耗品
- ラボサービス
サンプルタイプ別
- 呼気
- 唾液
- 髪
- 尿
- その他
エンドユーザー別
- 病院
- 職場
- 薬物検査ラボ
- 刑事司法制度・法執行機関
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
企業別の市場シェア

第5章世界の薬剤スクリーニング市場の展望：地域別

北米
欧州
南米
アジア太平洋
中東・アフリカ

第6章市場マッピング

コンポーネント別
サンプル別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長阻害要因 (課題・抑制要因)

第9章規制の枠組みとイノベーション

特許の情勢
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析（主要企業）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Abbott Laboratories
Alfa Scientific Designs Inc.
Bio-Rad Laboratories, Inc.
Drager Group
Thermo Fisher Scientific
Siemens Healthineers company
Psychemedics Corporation
OraSure Technologies, Inc.
Omega Laboratories, Inc.
Laboratory Corporation of America Holdings

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 2.Global Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 3.Global Drug Screening Market Share (%), By Components, 2017-2031F
Figure 4.Global Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 5.Global Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 6.Global Drug Screening Market Share (%), By Region, 2017-2031F
Figure 7.North America Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 8.North America Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 9.North America Drug Screening Market Share (%), By Components, 2017-2031F
Figure 10.North America Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 11.North America Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 12.North America Drug Screening Market Share (%), By Country, 2017-2031F
Figure 13.United States Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 14.United States Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 15.United States Drug Screening Market Share (%), By Components, 2017-2031F
Figure 16.United States Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 17.United States Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 18.Canada Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 19.Canada Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 20.Canada Drug Screening Market Share (%), By Components, 2017-2031F
Figure 21.Canada Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 22.Canada Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 23.Mexico Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 24.Mexico Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 25.Mexico Drug Screening Market Share (%), By Components, 2017-2031F
Figure 26.Mexico Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 27.Mexico Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 28.Europe Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 29.Europe Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 30.Europe Drug Screening Market Share (%), By Components, 2017-2031F
Figure 31.Europe Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 32.Europe Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Drug Screening Market Share (%), By Country, 2017-2031F
Figure 34.Germany Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 35.Germany Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 36.Germany Drug Screening Market Share (%), By Components, 2017-2031F
Figure 37.Germany Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 38.Germany Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 39.France Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 40.France Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 41.France Drug Screening Market Share (%), By Components, 2017-2031F
Figure 42.France Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 43.France Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 44.Italy Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 45.Italy Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 46.Italy Drug Screening Market Share (%), By Components, 2017-2031F
Figure 47.Italy Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 48.Italy Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 49.United Kingdom Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 50.United Kingdom Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 51.United Kingdom Drug Screening Market Share (%), By Components, 2017-2031F
Figure 52.United Kingdom Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 53.United Kingdom Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 54.Russia Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 55.Russia Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 56.Russia Drug Screening Market Share (%), By Components, 2017-2031F
Figure 57.Russia Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 58.Russia Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 59.Netherlands Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 60.Netherlands Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 61.Netherlands Drug Screening Market Share (%), By Components, 2017-2031F
Figure 62.Netherlands Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 63.Netherlands Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 64.Spain Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 65.Spain Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 66.Spain Drug Screening Market Share (%), By Components, 2017-2031F
Figure 67.Spain Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 68.Spain Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 69.Turkey Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 70.Turkey Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 71.Turkey Drug Screening Market Share (%), By Components, 2017-2031F
Figure 72.Turkey Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 73.Turkey Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 74.Poland Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 75.Poland Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 76.Poland Drug Screening Market Share (%), By Components, 2017-2031F
Figure 77.Poland Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 78.Poland Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 79.South America Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 80.South America Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 81.South America Drug Screening Market Share (%), By Components, 2017-2031F
Figure 82.South America Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 83.South America Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 84.South America Drug Screening Market Share (%), By Country, 2017-2031F
Figure 85.Brazil Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 86.Brazil Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 87.Brazil Drug Screening Market Share (%), By Components, 2017-2031F
Figure 88.Brazil Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 89.Brazil Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 90.Argentina Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 91.Argentina Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 92.Argentina Drug Screening Market Share (%), By Components, 2017-2031F
Figure 93.Argentina Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 94.Argentina Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 95.Asia-Pacific Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 96.Asia-Pacific Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 97.Asia-Pacific Drug Screening Market Share (%), By Components, 2017-2031F
Figure 98.Asia-Pacific Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 99.Asia-Pacific Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 100.Asia-Pacific Drug Screening Market Share (%), By Country, 2017-2031F
Figure 101.India Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 102.India Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 103.India Drug Screening Market Share (%), By Components, 2017-2031F
Figure 104.India Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 105.India Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 106.China Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 107.China Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 108.China Drug Screening Market Share (%), By Components, 2017-2031F
Figure 109.China Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 110.China Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 111.Japan Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 112.Japan Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 113.Japan Drug Screening Market Share (%), By Components, 2017-2031F
Figure 114.Japan Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 115.Japan Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 116.Australia Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 117.Australia Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 118.Australia Drug Screening Market Share (%), By Components, 2017-2031F
Figure 119.Australia Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 120.Australia Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 121.Vietnam Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 122.Vietnam Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 123.Vietnam Drug Screening Market Share (%), By Components, 2017-2031F
Figure 124.Vietnam Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 125.Vietnam Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 126.South Korea Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 127.South Korea Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 128.South Korea Drug Screening Market Share (%), By Components, 2017-2031F
Figure 129.South Korea Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 130.South Korea Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 131.Indonesia Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 132.Indonesia Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 133.Indonesia Drug Screening Market Share (%), By Components, 2017-2031F
Figure 134.Indonesia Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 135.Indonesia Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 136.Philippines Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 137.Philippines Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 138.Philippines Drug Screening Market Share (%), By Components, 2017-2031F
Figure 139.Philippines Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 140.Philippines Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 141.Middle East & Africa Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 142.Middle East & Africa Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 143.Middle East & Africa Drug Screening Market Share (%), By Components, 2017-2031F
Figure 144.Middle East & Africa Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 145.Middle East & Africa Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 146.Middle East & Africa Drug Screening Market Share (%), By Country, 2017-2031F
Figure 147.Saudi Arabia Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 148.Saudi Arabia Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 149.Saudi Arabia Drug Screening Market Share (%), By Components, 2017-2031F
Figure 150.Saudi Arabia Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 151.Saudi Arabia Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 152.UAE Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 153.UAE Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 154.UAE Drug Screening Market Share (%), By Components, 2017-2031F
Figure 155.UAE Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 156.UAE Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 157.South Africa Drug Screening Market, By Value, in USD Billion, 2017-2031F
Figure 158.South Africa Drug Screening Market, By Volume, in Million Units, 2017-2031F
Figure 159.South Africa Drug Screening Market Share (%), By Components, 2017-2031F
Figure 160.South Africa Drug Screening Market Share (%), By Sample Type, 2017-2031F
Figure 161.South Africa Drug Screening Market Share (%), By End-user, 2017-2031F
Figure 162.By Components Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163.By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11136

Global drug screening market is projected to witness a CAGR of 14.65% during the forecast period 2024-2031, growing from USD 7.02 billion in 2023 to USD 20.96 billion in 2031. Growth in the global drug screening market is driven by various factors, such as increasing alcohol and drug consumption, technological advancements in drug testing products, and increased implementation of strict rules and regulations regarding proper drug screening among the people to maintain discipline and safety measures. Growing investments in research and development activities, presence of several top players, and collaborative ventures, such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches, further accelerate the growth of the global drug screening market.

The global drug screening market is experiencing tremendous growth due to various key factors. One of the primary drivers is the increasing global consumption of drugs and alcohol, leading to an increased demand for drug screening services worldwide. Stringent regulations frameworks to enhance drug and alcohol testing are fueling the market's expansion. Additionally, excessive drug abuse leads to a rising burden of accidents, which has further accelerated the need for developing effective drug screening solutions. Government initiatives and support, such as granting funds, to manage and monitor drug abuse play a pivotal role in propelling market growth. The presence of key market players, along with continuous technological advancements in drug screening products, are enhancing their efficiency and effectiveness, thereby driving demand for more advanced solutions. Moreover, collaboration activities, such as mergers and acquisitions, distribution agreements, and partnerships, further accelerate growth of the global drug screening market.

For instance, in January 2024, OraSure Technologies, Inc., which is a global leader in diagnostics, announced that it has signed a distribution agreement with Sapphiros, which is a Boston-based diagnostics company. Through this strategic partnership, OraSure expects to develop cost-effective diagnostics tests and enhance its product portfolio, as well as expand its business globally.

Increasing Consumption of Psychoactive Substances

The increased consumption of drugs and alcohol is accelerating the drug screening market. Anxiety, stress, depression, isolation, and limited access to social help have contributed to higher drug abuse among the population. Rising cases of drug overdose, which leads to many adverse effects, such as accidents, self-destruction activities, and even death, have surged the need for drug screening services. For instance, according to World Drug Report 2023, the total number of drug users in the year 2021 was estimated to be 296 million. It is also estimated that cannabis is the most widely used drug by the population across the globe. This increasing drug abuse led to the global burden on health and health-care systems, emphasizing the importance of following strict drug screening activities. Additionally, drug screening plays an essential role in minimizing the growing cases of accidents, such as road traffic accidents, which is acting as a major factor flourishing the market growth.

Government Initiatives

The government plays a crucial role in managing and controlling the increased prevalence of drug abuse by continuously developing policies and programs to monitor drug abuse cases within the country. The government is involved in promoting research and development activities to develop highly efficient drug abuse detection products and devices. For instance, the National Institute on Drug Abuse, which is a federal agency that works on supporting scientific research on understanding and controlling drug abuse, emphasizes on promoting research and development activities to control global drug abuse. The federal agency brings concerns on various aspects of drug abuse, such as developing drug testing kits that can efficiently and accurately detect alcohol and drug consumption. Due to these frequent governmental support and initiatives, public and private diagnostics companies are excessively involved in developing innovative drug screening products and have increased investment activities, which is further improving the overall global drug screening market.

Increased Demand for Rapid Testing Devices

Among the component segment, rapid testing devices are gaining popularity, due to which this segment is expected to grow at a faster pace in the global drug screening market. These devices are easy to administer, are cost-effective, and give faster results due to which they are excessively used in the market. As the demand is rising, several leading players are launching this product in their product portfolio. For instance, in April 2023, MIP Discovery, which is a pioneer in developing reagents, announced the launch of "Novel nanoMIPTM affinity reagents" using its proprietary nanoMIPTM technology to detect opioid. This reagent is highly sensitive and robust in detecting opioid consumption. These latest launches by key companies in this segment are expected to enhance growth in the global drug screening market.

Growing Demand for Oral Fluid Samples-based Testing Kits

Among the sample type segment, oral fluids, such as saliva-based samples, are expected to show significant growth in the future. There have been increased investments and research and development activities to develop oral fluid sample-based diagnostics kits by several leading players, which is accelerating market growth. For instance, Alfa Scientific Designs Inc., which is a global leader in the development and manufacturing of rapid immunoassay point-of-care tests, states in its latest article that saliva testing has gained tremendous growth over the past few years. Several rapid diagnostic test manufacturers have claimed that saliva samples give faster results compared to other samples. Additionally, saliva samples possess several benefits over other samples as they can be done anywhere, anytime, do not require other tools and appliances for data collection, and do not have any privacy issue. Due to these potential benefits of saliva-based tests, several leading players prefer to invest in developing diagnostics kits that use saliva samples to detect drug abuse, further enhancing their product portfolio and leading to the growth of global drug screening market.

North America Holds the Maximum Share in the Market

North America dominates the global drug screening market due to its robust healthcare system and implementation of strict rules and regulations regarding drug abuse. The availability of technologically advanced drug screening kits and their high efficiency in detecting drug usage further propels the drug screening market in the region. Additionally, the increasing prevalence of drug abuse in the United States is compelling the requirement for efficient drug screening products, thereby significantly impacting the market growth. For instance, according to the U.S. National Center for Drug Abuse Statistics, around 19.4% of U.S population have used illegal drugs at least once in the year 2021. Additionally, The Journal of the American Medical Association report also states that between January 2021 and June 2021, approximately 1,150 youngsters within the age group of 14 to 18 died from drug overdose. Due to this increasing number of people involved in excessive drug and alcohol consumption, there has been a substantial need for drug screening activities to combat the increasing number of drug abuse cases in the region.

Future Market Scenario (2024 - 2031F)

The global drug screening market is expected to grow in the future, primarily due to increased global consumption of drugs and alcohol, stringent rules and regulations on drug testing, and government initiatives and support to combat drug abuse. Additionally, technological advancements and increased investments by public and private diagnostics manufacturers will lead to the development of more efficient drug screening products, thereby creating lucrative market opportunities. Moreover, favorable regulatory frameworks that help in faster FDA approvals, while maintaining the accuracy and efficacy of the drug testing devices, further accelerate the growth of the global drug screening market.

Key Players Landscape and Outlook

In the drug screening market, several leading players are frequently undergoing strategic partnerships and distribution agreements, which play a pivotal role in propelling the global drug screening market's expansion. These partnership agreements empower companies to gain informative insights regarding the latest trends in the market, access each other's resources, and technologies, and invest in research and development activities to enhance and innovate product offerings. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development, and contribute to the enduring and tremendous growth of the global market. For instance, in February 2023, Omega Laboratories, which is a global leader in providing laboratory testing solutions, announced that it has established a strategic partnership with Life Diagnostics, which is among the UAE's fastest-growing company in diagnostics. This partnership aims to establish a new drugs of abuse testing laboratory in the country, which is expected to lead the growth of the Middle East and Africa region in the global drug screening market.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Drug Screening Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Components
- 4.2.1.Rapid Testing Devices
  - 4.2.1.1.Urine Testing Devices
  - 4.2.1.2.Oral Fluid Testing Devices
- 4.2.2.Equipment
  - 4.2.2.1.Breath Analyzers
  - 4.2.2.2.Immunoassay Analyzers
  - 4.2.2.3.Chromatography Instruments
- 4.2.3.Consumables
  - 4.2.3.1.Assay Kits
  - 4.2.3.2.Sample Collection Cups
  - 4.2.3.3.Calibrators and Controls
  - 4.2.3.4.Others
- 4.2.4.Laboratory Services
4.3.By Sample Type
- 4.3.1.Breath
- 4.3.2.Oral Fluid
- 4.3.3.Hair
- 4.3.4.Urine
- 4.3.5.Others
4.4.By End-user
- 4.4.1.Hospital
- 4.4.2.Workplaces
- 4.4.3.Drug Testing Laboratories
- 4.4.4.Criminal Justice System and Law Enforcement Agencies
- 4.4.5.Others
4.5.By Region
- 4.5.1.North America
- 4.5.2.Europe
- 4.5.3.Asia-Pacific
- 4.5.4.South America
- 4.5.5.Middle East and Africa
4.6.By Company Market Share (%), 2023

5.Global Drug screening Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Components
  - 5.1.2.1.Rapid Testing Devices
  - 5.1.2.1.1.Urine Testing Devices
  - 5.1.2.1.2.Oral Fluid Testing Devices
  - 5.1.2.2.Equipment
  - 5.1.2.2.1.Breath Analyzers
  - 5.1.2.2.2.Immunoassay Analyzers
  - 5.1.2.2.3.Chromatography Instruments
  - 5.1.2.3.Consumables
  - 5.1.2.3.1.Assay Kits
  - 5.1.2.3.2.Sample Collection Cups
  - 5.1.2.3.3.Calibrators and Controls
  - 5.1.2.3.4.Others
  - 5.1.2.4.Laboratory Services
- 5.1.3.By Sample Type
  - 5.1.3.1.Breath
  - 5.1.3.2.Oral Fluid
  - 5.1.3.3.Hair
  - 5.1.3.4.Urine
  - 5.1.3.5.Others
- 5.1.4.By End-user
  - 5.1.4.1.Hospital
  - 5.1.4.2.Workplaces
  - 5.1.4.3.Drug Testing Laboratories
  - 5.1.4.4.Criminal Justice System and Law Enforcement Agencies
  - 5.1.4.5.Others
- 5.1.5.United States*
  - 5.1.5.1.Market Size & Forecast
  - 5.1.5.1.1.By Value
  - 5.1.5.1.2.By Volume
  - 5.1.5.2.By Components
  - 5.1.5.2.1.Rapid Testing Devices
  - 5.1.5.2.1.1.Rapid Testing Devices
  - 5.1.5.2.1.2.Urine Testing Devices
  - 5.1.5.2.1.3.Oral Fluid Testing Devices
  - 5.1.5.2.2.Equipment
  - 5.1.5.2.2.1.Breath Analyzers
  - 5.1.5.2.2.2.Immunoassay Analyzers
  - 5.1.5.2.2.3.Chromatography Instruments
  - 5.1.5.2.3.Consumables
  - 5.1.5.2.3.1.Assay Kits
  - 5.1.5.2.3.2.Sample Collection Cups
  - 5.1.5.2.3.3.Calibrators and Controls
  - 5.1.5.2.3.4.Others
  - 5.1.5.2.4.Laboratory Services
  - 5.1.5.3.By Sample Type
  - 5.1.5.3.1.Breath
  - 5.1.5.3.2.Oral Fluid
  - 5.1.5.3.3.Hair
  - 5.1.5.3.4.Urine
  - 5.1.5.3.5.Others
  - 5.1.5.4.By End-user
  - 5.1.5.4.1.Hospital
  - 5.1.5.4.2.Workplaces
  - 5.1.5.4.3.Drug Testing Laboratories
  - 5.1.5.4.4.Criminal Justice System and Law Enforcement Agencies
  - 5.1.5.4.5.Others
- 5.1.6.Canada
- 5.1.7.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Components
6.2.By Sample Type
6.3.By End-user
6.4.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Patent Landscape
9.2.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Abbott Laboratories
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Alfa Scientific Designs Inc.
13.3.Bio-Rad Laboratories, Inc.
13.4.Drager Group
13.5.Thermo Fisher Scientific
13.6.Siemens Healthineers company
13.7.Psychemedics Corporation
13.8.OraSure Technologies, Inc.
13.9.Omega Laboratories, Inc.
13.10.Laboratory Corporation of America Holdings

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

薬剤スクリーニング市場の評価：コンポーネント・サンプルタイプ・エンドユーザー・地域別の機会および予測 (2017～2031年)

Drug screening Market Assessment, By Components, By Sample Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の薬剤スクリーニング市場の展望

第5章世界の薬剤スクリーニング市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Drug Screening Market Outlook, 2017-2031F

5.Global Drug screening Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

薬剤スクリーニング市場の評価：コンポーネント・サンプルタイプ・エンドユーザー・地域別の機会および予測 (2017～2031年)

Drug screening Market Assessment, By Components, By Sample Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の薬剤スクリーニング市場の展望

第5章 世界の薬剤スクリーニング市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Drug Screening Market Outlook, 2017-2031F

5.Global Drug screening Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の薬剤スクリーニング市場の展望

第5章世界の薬剤スクリーニング市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項